TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8627643
Drug: 5-FU at
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU at 300 mg/m2 per day by continuous infusion plus weekly cisplatin at 20 mg/m2 (Treatment D)
Study: 8627643
Drug: Bolus 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bolus 5-FU at 500 mg/m2 for 5 days followed in 2 weeks by weekly bolus 5-FU at 600 mg/m2 plus weekly cisplatin at 20 mg/m2 (Treatment B)
Study: 6362905
Drug: 0.3 mg/day
Normalized name: cloNIDine HCl 0.3 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/day clonidine for 3 days
Study: 6362905
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg iv naloxone
Study: 6362905
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment with naloxone
Study: 6362905
Drug: Clonidine treatment
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine treatment with naloxone
Study: 26852904
Drug: GLPG0974 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG0974 (single doses up to 250 mg)
Study: 26852904
Drug: GLPG0974 (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG0974 (multiple daily doses up to 400 mg for 14 days)
Study: 20414532
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of salt/day for 7 days (Phase 1)
Study: 20414532
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g of salt/day (subgroup 1, Phase 2)
Study: 20414532
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of salt/day (subgroup II, Phase 2)
Study: 14617582
Drug: Edrophonium (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium (0.5 mg x kg(‐1))
Study: 10745385
Drug: Albendazole 600
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole 600 mg every six months
Study: 8955968
Drug: Mixed group
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed group (mepivacaine 1% with 0.1 mg fentanyl)
Study: 22374468
Drug: Nizatidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine (150 mg)
Study: 16429411
Drug: Bilateral continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral continuous intraputamenal infusion of liatermin 15 microg/putamen/day
Study: 7955745
Drug: Supine and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supine and upright radionuclide esophageal transit (RET) before treatment
Study: 31328871
Drug: Human umbilical
Normalized name: Human umbilical tissue derived cells
DrugBank: Human umbilical tissue derived cells (DB17907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human umbilical cord blood-derived mesenchymal stem cell (hUCBMSC)-conditioned media containing cream with serum
Study: 31328871
Drug: Human umbilical
Normalized name: Human umbilical tissue derived cells
DrugBank: Human umbilical tissue derived cells (DB17907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human umbilical cord blood-derived mesenchymal stem cell (hUCBMSC)-conditioned media containing cream without serum
Study: 29482586
Drug: Culturally adapted
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally adapted internet-delivered cognitive behavioural therapy (iCBT) Space from Depression, consisting of 7 weekly modules with post-session feedback support.
Study: 29482586
Drug: Waiting-list control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting-list control group (no active treatment).
Study: 26658227
Drug: DPYD c.1129-5923
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPYD c.1129-5923 C>G and hapB3 variants
Study: 26658227
Drug: DPYD c.1129-5923
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPYD c.1129-5923 C>G/hapB3
Study: 23833846
Drug: Intrathecal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal fentanyl with 0.1 mg morphine
Study: 20666786
Drug: 8 mm,
Normalized name: Steri-Tamp Seal, 28 mm, blue
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mm, v4.1 mm Straumann Standard Plus tissue-level implants (Group A)
Study: 20666786
Drug: 10 mm,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mm, v4.1 mm Straumann Standard Plus tissue-level implants (Group B)
Study: 14744403
Drug: Therapeutic options
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic options for hand dermatitis, including treatments for recalcitrant cases.
Study: 10839658
Drug: Fozivudine tidoxil
Normalized name: Fozivudine Tidoxil
DrugBank: Fozivudine Tidoxil (DB12423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fozivudine tidoxil (FZD) 200 mg daily
Study: 10839658
Drug: Fozivudine tidoxil
Normalized name: Fozivudine Tidoxil
DrugBank: Fozivudine Tidoxil (DB12423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fozivudine tidoxil (FZD) 400 mg daily
Study: 10839658
Drug: Fozivudine tidoxil
Normalized name: Fozivudine Tidoxil
DrugBank: Fozivudine Tidoxil (DB12423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fozivudine tidoxil (FZD) 200 mg twice daily
Study: 10839658
Drug: Fozivudine tidoxil
Normalized name: Fozivudine Tidoxil
DrugBank: Fozivudine Tidoxil (DB12423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fozivudine tidoxil (FZD) 800 mg daily
Study: 10839658
Drug: Fozivudine tidoxil
Normalized name: Fozivudine Tidoxil
DrugBank: Fozivudine Tidoxil (DB12423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fozivudine tidoxil (FZD) 400 mg twice daily
Study: 10839658
Drug: Fozivudine tidoxil
Normalized name: Fozivudine Tidoxil
DrugBank: Fozivudine Tidoxil (DB12423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fozivudine tidoxil (FZD) 600 mg twice daily
Study: 8977752
Drug: Intravenous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous insulin 0.2 IU/kg
Study: 8977752
Drug: Intravenous arginine
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous arginine 20 g/m2
Study: 8977752
Drug: Intramuscular glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intramuscular glucagon 1 mg
Study: 8977752
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine 100 micrograms
Study: 8977752
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine 200 micrograms
Study: 1487621
Drug: Lorazepam 1
Normalized name: lorazepam 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 1 mg (positive internal control)
Study: 1487621
Drug: Paroxetine 20
Normalized name: PARoxetine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20 mg with alcohol (0.6 g/kg)
Study: 1487621
Drug: Lorazepam 1
Normalized name: lorazepam 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 1 mg with alcohol (0.6 g/kg)
Study: 26942445
Drug: Intragastric glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intragastric glucose loads of 10 g, 25 g, and 75 g glucose dissolved in 300 ml tap water.
Study: 24481874
Drug: Evolocumab (subcutaneous,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab (subcutaneous, administered every 2 weeks or every month for 12 weeks)
Study: 20104762
Drug: Wenxinkeli (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wenxinkeli (5 g, 3 times a day with warm water) for 4 weeks
Study: 20104762
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (adenosine triphosphate, coenzyme A, vitamin C, coenzyme Q10 and other nutrients cardiac drugs) for 4 weeks
Study: 14977792
Drug: Phenylephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine infusion at 100 microg/min for 2 min, then titrated to maintain SBP at 100% of baseline.
Study: 14977792
Drug: Phenylephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine infusion at 90% of baseline SBP.
Study: 14977792
Drug: Phenylephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine infusion at 80% of baseline SBP.
Study: 14977792
Drug: Phenylephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine infusion at 100% of baseline SBP.
Study: 11686426
Drug: Cefprozil, 500
Normalized name: Cefprozil, 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefprozil, 500 mg twice daily for 5 days
Study: 11686426
Drug: Clarithromycin, 500
Normalized name: Clarithromycin, 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin, 500 mg twice daily for 10 days
Study: 9784725
Drug: Enterosorbent polysorb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enterosorbent polysorb and a complex of antioxidants (tocoferolum acetatum, ascorbic acid, quercetin) as a supplement to conventional therapy (Group I, n = 76)
Study: 9784725
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy only (Group II, n = 67)
Study: 3280363
Drug: Domiodol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domiodol (0.5 mg/kg three times daily for 14 days)
Study: 11397997
Drug: Oral maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral maintenance treatment with ritodrine
Study: 11397997
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of β-sympathomimetics
Study: 11397997
Drug: Prolonged treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged treatment by β-sympathomimetics
Study: 22607850
Drug: aCRT (adaptive
Approvals — FDA: no, EMA: no, PMDA: no
Description: aCRT (adaptive cardiac resynchronization therapy)
Study: 17509304
Drug: Premarin 1.25
Normalized name: Premarin 1.25mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premarin 1.25 mg 3 times daily
Study: 17509304
Drug: Premarin 1.25
Normalized name: Premarin 1.25mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premarin 1.25 mg once daily
Study: 17509304
Drug: Premarin 1.25
Normalized name: Premarin 1.25mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premarin 1.25 mg 3 times daily and warfarin 1 mg
Study: 17509304
Drug: Premarin 1.25
Normalized name: Premarin 1.25mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premarin 1.25 mg once daily and warfarin 1 mg
Study: 16027621
Drug: Fränkel appliance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fränkel appliance therapy
Study: 12458696
Drug: Massage therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy, 20-minute sessions, twice a week for five weeks
Study: 12458696
Drug: Relaxation therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation therapy, 20-minute sessions, twice a week for five weeks
Study: 7019785
Drug: Sodium selenite
Normalized name: Sodium selenite
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Sodium selenite or selenomethionine (100 micrograms Se daily)
Study: 23058029
Drug: Amoxicillin and
Normalized name: omeprazole, amoxicillin and rifabutin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin and clavulanic acid
Study: 17473143
Drug: Chemoprophylaxis plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoprophylaxis plus intermittent pneumatic compression (more than six hours daily)
Study: 15148925
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg daily (qd) for 6 weeks
Study: 15148925
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg twice a day (bid) for 6 weeks
Study: 11939160
Drug: Gonadotrophin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotrophin-releasing hormone agonists (buserelin, leuprolide, triptorelin)
Study: 9690949
Drug: Itraconazole 100
Normalized name: itraconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 100 mg orally once daily for 4 days
Study: 7866002
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (points ST36, LI11, RN6, and symptomatic points bilaterally) for 30 minutes daily for 10 days
Study: 2562387
Drug: Guar gum
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar gum (15 g/day, divided in three doses with major meals)
Study: 18060379
Drug: TCR occurrence
Normalized name: AUTOLOGOUS CD4+ AND CD8+ T CELLS OBTAINED BY LEUKAPHERESIS, TRANSDUCED WITH AN HIV-DERIVED SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING AN ENHANCED-AFFINITY T CELL RECEPTOR (TCR) SPECIFIC FOR THE HUMAN MELANOMA ANTIGEN A4 (MAGE FAMILY MEMBER A4, A
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCR occurrence during nasal mucosa preparation
Study: 16764647
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg twice daily for 14 days
Study: 12971705
Drug: Routine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine therapy (RT) group received no professional rehabilitation therapy
Study: 11033383
Drug: Dose-response studies
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose-response studies in Phase I
Study: 11033383
Drug: Dose-response studies
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose-response studies in Phase II
Study: 11033383
Drug: Dose-response assessment
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose-response assessment
Study: 9436670
Drug: Intravenous immunoglobulins
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulins (Ig) administered between weeks 5 and 7 of gestation for 2 consecutive days, with a further infusion at week 8.
Study: 9436670
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered between weeks 5 and 7 of gestation for 2 consecutive days, with a further infusion at week 8.
Study: 8292687
Drug: Intravenous clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clonidine hydrochloride (2 micrograms/kg)
Study: 3538478
Drug: Metered dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered dose inhaler with conical spacer device
Study: 3538478
Drug: Metered dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered dose inhaler without conical spacer device
Study: 3538478
Drug: Nebuliser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebuliser treatment
Study: 20299485
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg aspirin once daily
Study: 24213952
Drug: Late parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late parenteral nutrition (PN) starting on day 8
Study: 17320568
Drug: 20% mannitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% mannitol 0.5 g/kg
Study: 17320568
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 2.5 mL/kg
Study: 11007673
Drug: Supine position
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supine position (Diuretic)
Study: 11007673
Drug: Upright position
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upright position (Diuretic)
Study: 6378422
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (nitrates and beta-blockers)
Study: 3511709
Drug: Erythromycin (333
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (333 mg three times daily by mouth for 7 days)
Study: 23615499
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (IV MeP)
Study: 21322282
Drug: Ganciclovir (induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganciclovir (induction and maintenance treatment)
Study: 9200528
Drug: Paroxetine doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine doses ranged from 10 to 40 mg/day
Study: 1555692
Drug: Long protocol
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long protocol (subcutaneous buserelin acetate 200 micrograms/d from day 1, hMG started after 14 days)
Study: 1555692
Drug: Short protocol
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short protocol (subcutaneous buserelin acetate 200 micrograms/d from day 2, hMG from day 3)
Study: 3904102
Drug: Methylprednisolone (MPN)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (MPN) 375 mg administered in 3 equal doses IV just prior to chemotherapy and then IM 6 and 12 hours after treatment
Study: 3904102
Drug: Metoclopramide (MCP)
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoclopramide (MCP) 1 mg/kg administered in 3 equal doses IV just prior to chemotherapy and then IM 6 and 12 hours after treatment
Study: 30107488
Drug: 120 g
Normalized name: soap 120 gram TOPICAL BAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 g full-fat Irish cheddar cheese (FFCC)
Study: 30107488
Drug: Butter (49
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butter (49 g), calcium caseinate powder (30 g), and Ca supplement (CaCO3) (500 mg) (BCC)
Study: 30107488
Drug: 120 g
Normalized name: soap 120 gram TOPICAL BAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 g reduced-fat Irish cheddar cheese + butter (21 g) (RFC + B)
Study: 30107488
Drug: 120 g
Normalized name: soap 120 gram TOPICAL BAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 g FFCC (as per A) after a 6-wk run-in period
Study: 25481088
Drug: Intramuscular testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular testosterone administration once per week for 8 weeks starting 2 weeks prior to surgery
Study: 18511650
Drug: Abetimus sodium
Normalized name: abetimus sodium
DrugBank: Abetimus (DB06662)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abetimus sodium 600 mg
Study: 18511650
Drug: Abetimus sodium
Normalized name: abetimus sodium
DrugBank: Abetimus (DB06662)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abetimus sodium 1200 mg
Study: 18511650
Drug: Abetimus sodium
Normalized name: abetimus sodium
DrugBank: Abetimus (DB06662)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abetimus sodium 2400 mg
Study: 18511650
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of abetimus sodium
Study: 16425357
Drug: Combined medication
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined medication (Control group)
Study: 12874182
Drug: Lotrafiban 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotrafiban 30 or 50 mg BID
Study: 12874182
Drug: Aspirin >162
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin >162 mg/d
Study: 10649829
Drug: Sumatriptan (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan (6 mg SQ)
Study: 8657986
Drug: Valerian and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valerian and hops tablets
Study: 8657986
Drug: Valerian syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valerian syrup
Study: 8281625
Drug: Droloxifene 20
Normalized name: Droloxifene
DrugBank: Droloxifene (DB15641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droloxifene 20 mg
Study: 8281625
Drug: Droloxifene 40
Normalized name: Droloxifene
DrugBank: Droloxifene (DB15641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droloxifene 40 mg
Study: 8281625
Drug: Droloxifene 100
Normalized name: Droloxifene
DrugBank: Droloxifene (DB15641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droloxifene 100 mg
Study: 1515258
Drug: Droloxifene (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droloxifene (all doses)
Study: 6394143
Drug: Tolfenamic acid
Normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolfenamic acid (200 mg)
Study: 6394143
Drug: Tolfenamic acid
Normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolfenamic acid + Caffeine (200 mg + 100 mg)
Study: 6394143
Drug: Tolfenamic acid
Normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolfenamic acid + Metoclopramide (200 mg + 10 mg)
Study: 31032783
Drug: Topical minoxidil
Normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical minoxidil 5% lotion applied twice daily
Study: 31032783
Drug: Mesotherapy injected
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesotherapy injected once weekly
Study: 24657006
Drug: Group cognitive-behavioral
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive-behavioral therapy (module theme: people-themed)
Study: 24657006
Drug: Group cognitive-behavioral
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive-behavioral therapy (module theme: thoughts-themed)
Study: 21851027
Drug: PCEA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA with 0.125% bupivacaine and fentanyl (2 mcg/ml) with adrenaline (2 mcg/ml) (ABF group)
Study: 21851027
Drug: PCEA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA with 0.125% bupivacaine and fentanyl (2 mcg/ml) without adrenaline (BF group)
Study: 19138601
Drug: Moxifloxacin (MXF)
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin (MXF) 400 mg/24 hours for 5 days
Study: 19138601
Drug: Amoxicillin and
Normalized name: omeprazole, amoxicillin and rifabutin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin and clavulanic acid (AMX-CLV) 500/125 mg/8 hours for 5 days
Study: 11230488
Drug: High-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon alfa-2b (IFNalpha2b)